Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,211 | 0,261 | 30.09. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
00:26 | Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC | 216 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA)High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while this... ► Artikel lesen | |
11.09. | Cantargia Closes the Acquisition of CAN10 by Otsuka | 253 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Otsuka's... ► Artikel lesen | |
CANTARGIA Aktie jetzt für 0€ handeln | |||||
29.08. | Cantargia im Q2 2025: Otsuka-Deal bringt 33 Mio. USD Sofortzahlung bei durchwachsenen klinischen Ergebnissen | 5 | Investing.com Deutsch | ||
29.08. | Cantargia Q2 2025 slides: Otsuka deal brings $33M upfront amid mixed clinical results | 2 | Investing.com | ||
27.08. | Cantargia Granted Important US Patent for Nadunolimab | 192 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the patent... ► Artikel lesen | |
21.08. | Cantargia: Aktie gibt trotz 630-Mio.-Dollar-Deal mit Otsuka nach | 5 | Investing.com Deutsch | ||
21.08. | Cantargia Publishes Half-Year Report 2025 | 292 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025."I started my tenure as interim CEO with... ► Artikel lesen | |
18.08. | Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer | 335 | ACCESS Newswire | Dr Steineger's appointment will be effective from September 1.She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and business... ► Artikel lesen | |
12.08. | Invitation to the Presentation of Cantargia's H1 2025 Report | 245 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 12, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August... ► Artikel lesen | |
17.07. | Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer | 393 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated... ► Artikel lesen | |
16.07. | Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer | 327 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 16, 2025 / Cantargia (STO:CANTA)Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival... ► Artikel lesen | |
15.07. | Otsuka to acquire Cantargia's CAN10 for autoimmune diseases | 4 | Pharmaceutical Technology | ||
15.07. | Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical | 422 | ACCESS Newswire | Cantargia receives an upfront cash payment of USD 33 million.Cantargia is eligible to receive up to USD 580 million in development, regulatory and commercial milestone payments plus earn-out payments... ► Artikel lesen | |
17.06. | Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans | 328 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 million... ► Artikel lesen | |
17.06. | Cantargia Q1 2025 slides: CAN10 advances amid funding challenges | 3 | Investing.com | ||
11.06. | Cantargia's Nadunolimab Aantibody Awarded US FDA Fast Track Designation | 808 | ACCESS Newswire | Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further development... ► Artikel lesen | |
19.05. | Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation | 261 | ACCESS Newswire | IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques.IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1,... ► Artikel lesen | |
15.05. | Bulletin from the Annual General Meeting in Cantargia AB | 329 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following:That no dividend would be paid.To discharge... ► Artikel lesen | |
13.05. | Cantargia Publishes Interim Report for the First Quarter of 2025 | 470 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025."The first... ► Artikel lesen | |
12.05. | Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2 | 297 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA)Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort.Model... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 84,10 | +0,12 % | BioNTech-Aktie am Scheideweg: Durchbruch bei Krebs oder weiterer Absturz durch US-Politik? | BioNTech feiert Fortschritte bei Krebsimmuntherapien. Doch in den USA drohen politische Hürden, die Aktie ins Wanken zu bringen. Vor wenigen Jahren galt BioNTech als strahlender Gewinner der Pandemie.... ► Artikel lesen | |
EVOTEC | 6,188 | +1,94 % | Evotec Aktie: Das könnte sich rächen... | Bei der Evotec Aktie gab es seit November 2024 immer wieder gescheiterte Versuche, die 200-Tage-Linie zu überwinden. Mit der aktuellen Erholungsbewegung bei der Biotech-Aktie scheint es gar nicht so... ► Artikel lesen | |
QIAGEN | 37,695 | +0,20 % | ROUNDUP/Aktien Frankfurt Eröffnung: Moderate Verluste - Richtungssuche | FRANKFURT (dpa-AFX) - Nach den leichten Gewinnen vom Vortag haben die Anleger am deutschen Aktienmarkt am Donnerstag wieder etwas auf die Bremse getreten. "Die Richtungssuche geht weiter", konstatierte... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 488,00 | +1,88 % | Regeneron Reports FDA Approval Extending Indication Of Evkeeza | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the FDA has approved Evkeeza ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the... ► Artikel lesen | |
BRAIN BIOTECH | 2,260 | +2,73 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech ernennt Johan Jansén-Storbacka zum Executive Vice President BRAINBiocatalysts für den Bereich Enzymprodukte | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Personalie
BRAIN Biotech ernennt Johan Jansén-Storbacka zum Executive Vice President BRAINBiocatalysts für den Bereich Enzymprodukte... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
CARDIOL THERAPEUTICS | 0,910 | -0,44 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
BURCON NUTRASCIENCE | 1,460 | +0,69 % | Burcon NutraScience Corporation: Burcon Announces New Board Members and Results of Shareholder Meeting | Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
CSL | 112,06 | +0,29 % | Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy | FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss
ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/... ► Artikel lesen | |
MANNKIND | 4,624 | +0,98 % | MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer | WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products... ► Artikel lesen | |
OCULAR THERAPEUTIX | 10,135 | +1,74 % | Ocular Therapeutix Prices Offering Of 37.9 Mln Common Shares At $12.53/Shr | ||
OXFORD NANOPORE TECHNOLOGIES | 1,742 | -1,25 % | Oxford Nanopore Technologies: ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology | New adventitious viral agent (AVA) detection test offers rapid, sensitive, and affordable viral screening for biomanufacturers
ViruSure, a global leader in pathogen safety testing for biopharmaceuticals... ► Artikel lesen | |
ADAPTIMMUNE THERAPEUTICS | 0,112 | 0,00 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
CODEXIS | 2,134 | +2,89 % | Benchmark reiterates Hold rating on Codexis stock after Q2 results | ||
TELO GENOMICS | 0,038 | -5,00 % | Telo Genomics Corp.: Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update | Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for... ► Artikel lesen |